Laekna (2105 HK)

Laekna is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer, metabolic diseases, and liver fibrosis. Its pipeline includes drug candidates such as LAE002 for breast and prostate cancer, LAE001 for prostate cancer, and LAE102 for obesity. The company was founded in 2016 and is headquartered in Yuyao, China.